Lonza Group Ag (OTCMKTS:LZAGY) Short Interest Down 70.1% in June

Lonza Group Ag (OTCMKTS:LZAGYGet Free Report) was the recipient of a significant decline in short interest during the month of June. As of June 15th, there was short interest totaling 8,286 shares, a decline of 70.1% from the May 31st total of 27,683 shares. Based on an average daily volume of 150,990 shares, the days-to-cover ratio is currently 0.1 days. Currently, 0.0% of the company’s stock are short sold.

Analyst Ratings Changes

Separately, Zacks Research raised Lonza Group from a “strong sell” rating to a “hold” rating in a research report on Wednesday, April 8th. One investment analyst has rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy”.

View Our Latest Report on Lonza Group

Lonza Group Stock Down 0.6%

LZAGY stock traded down $0.38 on Friday, hitting $65.94. The company had a trading volume of 25,074 shares, compared to its average volume of 64,514. The company has a current ratio of 2.24, a quick ratio of 1.77 and a debt-to-equity ratio of 0.42. Lonza Group has a 12-month low of $58.53 and a 12-month high of $73.85. The stock’s 50-day simple moving average is $62.75 and its 200 day simple moving average is $65.19.

About Lonza Group

(Get Free Report)

Lonza Group is a Swiss multinational life sciences company that provides products and services to the pharmaceutical, biotech and specialty ingredients markets. Headquartered in Switzerland, the company operates globally with manufacturing and research facilities across Europe, North America and Asia, serving customers involved in drug discovery, development and commercial production. Lonza’s client base ranges from large pharmaceutical firms to emerging biotech companies and manufacturers of consumer health and specialty chemical products.

The company’s core activities center on contract development and manufacturing (CDMO) for small molecules and biologics, including process development, clinical and commercial-scale manufacturing, and fill–finish services.

Featured Articles

Receive News & Ratings for Lonza Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lonza Group and related companies with MarketBeat.com's FREE daily email newsletter.